3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
10
Neoplasms
3
Fallopian Tube Neoplasms
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Brain Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
SCLC,Extensive Stage
1
Rare Tumor
1
Penile Neoplasms
1
Pathologic Complete Response
1
Pancreatic Adenocarcinoma Metastatic
1
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
1
Ovarian Carcinosarcoma
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Hemangiosarcoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Cystadenocarcinoma, Serous
1
Carcinoma, Ovarian Epithelial
1
Carcinoma
1
Biliary Tract Neoplasms
1
Advanced Solid Tumor
1
Interventions
penpulimab
1
niraparib
1
anlotinib
1
Taxes
1
Ipilimumab
1
IFL protocol
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Pancreatic Adenocarcinoma Metastatic
×
niraparib
×
Clear all
NCT06747845
2025-09-16
ParpVax2
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
68 enrolled